ORIC PHARMACEUTICALS, INC. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
ORIC PHARMACEUTICALS, INC. (ORIC) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $1.04 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-02-23
- ORIC PHARMACEUTICALS, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $1.04M, a 11.99% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $926.00K, a 44.91% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $639.00K, a 14.52% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $558.00K.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $1.04M 10-K · filed 2026-02-23 |
| 2024-12-31 | $926.00K 10-K · filed 2026-02-23 |
| 2023-12-31 | $639.00K 10-K · filed 2025-02-18 |
| 2022-12-31 | $558.00K 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |